Trials / Completed
CompletedNCT00073541
A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer
An Open-Label Phase II Study in Subjects With Recurrent EGFR-Positive Ovarian Cancer to Investigate the Safety and Efficacy of EMD 72000 Administered as a Single Agent
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- EMD Serono · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
EMD 72000 is an experimental, biological drug. Studies in animals indicate that EMD 72000 blocks a factor found on the surface of many cancer cells. The factor is called epidermal growth factor receptor or EGFR. One type of cancer which frequently contains EGFR is ovarian cancer. This study will test the safety and effects of EMD 72000 in subjects with EGFR-positive recurrent ovarian cancer following standard treatment that has failed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EMD 72000 |
Timeline
- Start date
- 2003-04-01
- Primary completion
- 2004-03-01
- Completion
- 2004-08-01
- First posted
- 2003-11-26
- Last updated
- 2017-01-20
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00073541. Inclusion in this directory is not an endorsement.